PubTransformer

A site to transform Pubmed publications into these bibliographic reference formats: ADS, BibTeX, EndNote, ISI used by the Web of Knowledge, RIS, MEDLINE, Microsoft's Word 2007 XML.

Relationship Between Circulating Tumor Cells and Tissue Plasminogen Activator in Patients with Early Breast Cancer.

Abstract Cancer increases the risk of venous thromboembolism (VTE) and circulating tumor cells (CTCs) are associated with an increased risk of VTE and, thus, with increased D-dimers as a product of fibrinolysis. Tissue plasminogen activator (tPA) is one of the key enzymes in the fibrinolytic pathway. Its activity is crucial in maintaining the balance between blood coagulation and fibrinolysis. This study aimed to analyze the association between CTCs and tPA in patients with primary breast cancer before surgery.
PMID
Related Publications

Circulating tumour cell-derived plastin3 is a novel marker for predicting long-term prognosis in patients with breast cancer.

Circulating tumour cells are linked to plasma D-dimer levels in patients with metastatic breast cancer.

Matrix metalloproteinase 1 and circulating tumor cells in early breast cancer.

Relationship between circulating tumor cells and epithelial to mesenchymal transition in early breast cancer.

Relationship between circulating tumor cells, blood coagulation, and urokinase-plasminogen-activator system in early breast cancer patients.

Authors

Mayor MeshTerms

Epithelial-Mesenchymal Transition

Keywords

Breast cancer

circulating tumor cells

tissue plasminogen activator

Journal Title anticancer research
Publication Year Start




PMID- 28373442
OWN - NLM
STAT- MEDLINE
DA  - 20170404
DCOM- 20170413
LR  - 20170413
IS  - 1791-7530 (Electronic)
IS  - 0250-7005 (Linking)
VI  - 37
IP  - 4
DP  - 2017 Apr
TI  - Relationship Between Circulating Tumor Cells and Tissue Plasminogen Activator in 
      Patients with Early Breast Cancer.
PG  - 1787-1791
AB  - AIM: Cancer increases the risk of venous thromboembolism (VTE) and circulating
      tumor cells (CTCs) are associated with an increased risk of VTE and, thus, with
      increased D-dimers as a product of fibrinolysis. Tissue plasminogen activator
      (tPA) is one of the key enzymes in the fibrinolytic pathway. Its activity is
      crucial in maintaining the balance between blood coagulation and fibrinolysis.
      This study aimed to analyze the association between CTCs and tPA in patients with
      primary breast cancer before surgery. PATIENTS AND METHODS: This prospective
      study included 110 patients in whom CTCs were detected by quantitative reverse
      transcription polymerase chain reaction targeted at epithelial (CK19) or
      epithelial-mesenchymal transition (EMT)-associated genes[TWIST1, SNAI1, SNAI2,
      zinc finger E-box-binding homeobox 1 (ZEB1), forkhead box protein C2 (FOXC2)].
      Plasma tPA protein was detected using enzyme-linked immunosorbent assay (ELISA). 
      RESULTS: CTCs were detected in 31 (28.2%) patients. There was no association
      between plasma tPA and CTCs. Although on average, higher levels of tPA were
      detected in patients with CTCs expressing EMT-associated genes, this difference
      did not reach statistical significance. There was no association of plasma tPA
      with any of the observed patient or tumor characteristics. CONCLUSION: Even
      though the blood coagulation pathway may be activated in more aggressive disease 
      related to an elevated CTC count, in this study, we did not find any association 
      between CTCs and plasma concentrations of tPA.
CI  - Copyright(c) 2017, International Institute of Anticancer Research (Dr. George J. 
      Delinasios), All rights reserved.
FAU - Bystricky, Branislav
AU  - Bystricky B
AD  - Second Department of Medical Oncology, Faculty of Medicine, Comenius University, 
      Bratislava, Slovakia.
AD  - Department of Oncology, Faculty Hospital Trencin, Trencin, Slovakia.
FAU - Jurisova, Silvia
AU  - Jurisova S
AD  - Second Department of Medical Oncology, Faculty of Medicine, Comenius University, 
      Bratislava, Slovakia.
AD  - National Cancer Institute, Bratislava, Slovakia.
FAU - Karaba, Marian
AU  - Karaba M
AD  - National Cancer Institute, Bratislava, Slovakia.
AD  - Department of Surgery, Slovak Medical University, Bratislava, Slovakia.
FAU - Minarik, Gabriel
AU  - Minarik G
AD  - Institute of Molecular Biomedicine, Faculty of Medicine, Comenius University,
      Bratislava, Slovakia.
FAU - Benca, Juraj
AU  - Benca J
AD  - National Cancer Institute, Bratislava, Slovakia.
AD  - Department of Medicine, St. Elizabeth University, Bratislava, Slovakia.
FAU - Sedlackova, Tatiana
AU  - Sedlackova T
AD  - Institute of Molecular Biomedicine, Faculty of Medicine, Comenius University,
      Bratislava, Slovakia.
FAU - Tothova, Lubomira
AU  - Tothova L
AD  - Institute of Molecular Biomedicine, Faculty of Medicine, Comenius University,
      Bratislava, Slovakia.
FAU - Vlkova, Barbora
AU  - Vlkova B
AD  - Institute of Molecular Biomedicine, Faculty of Medicine, Comenius University,
      Bratislava, Slovakia.
FAU - Cierna, Zuzana
AU  - Cierna Z
AD  - Department of Pathology, Faculty of Medicine, Comenius University, Bratislava,
      Slovakia.
FAU - Janega, Pavol
AU  - Janega P
AD  - Department of Pathology, Faculty of Medicine, Comenius University, Bratislava,
      Slovakia.
AD  - Institute of Normal and Pathological Physiology, Bratislava, Slovakia.
FAU - Manasova, Denisa
AU  - Manasova D
AD  - Translational Research Unit, Faculty of Medicine, Comenius University,
      Bratislava, Slovakia.
FAU - Gronesova, Paulina
AU  - Gronesova P
AD  - Cancer Research Institute, Slovak Academy of Sciences, Bratislava, Slovakia.
FAU - Pindak, Daniel
AU  - Pindak D
AD  - National Cancer Institute, Bratislava, Slovakia.
AD  - Department of Surgery, Slovak Medical University, Bratislava, Slovakia.
FAU - Mardiak, Jozef
AU  - Mardiak J
AD  - Second Department of Medical Oncology, Faculty of Medicine, Comenius University, 
      Bratislava, Slovakia.
AD  - National Cancer Institute, Bratislava, Slovakia.
FAU - Celec, Peter
AU  - Celec P
AD  - Institute of Molecular Biomedicine, Faculty of Medicine, Comenius University,
      Bratislava, Slovakia.
FAU - Mego, Michal
AU  - Mego M
AD  - Second Department of Medical Oncology, Faculty of Medicine, Comenius University, 
      Bratislava, Slovakia [email protected]
AD  - National Cancer Institute, Bratislava, Slovakia.
AD  - Translational Research Unit, Faculty of Medicine, Comenius University,
      Bratislava, Slovakia.
LA  - eng
PT  - Journal Article
PL  - Greece
TA  - Anticancer Res
JT  - Anticancer research
JID - 8102988
RN  - 0 (Biomarkers, Tumor)
RN  - EC 3.4.21.68 (Tissue Plasminogen Activator)
SB  - IM
MH  - Adult
MH  - Aged
MH  - Aged, 80 and over
MH  - Biomarkers, Tumor/*blood
MH  - Breast Neoplasms/*blood/*pathology
MH  - Enzyme-Linked Immunosorbent Assay
MH  - *Epithelial-Mesenchymal Transition
MH  - Female
MH  - Follow-Up Studies
MH  - Humans
MH  - Immunoenzyme Techniques
MH  - Middle Aged
MH  - Neoplasm Grading
MH  - Neoplasm Invasiveness
MH  - Neoplasm Staging
MH  - Neoplastic Cells, Circulating/*pathology
MH  - Prognosis
MH  - Prospective Studies
MH  - Survival Rate
MH  - Tissue Plasminogen Activator/*blood
OTO - NOTNLM
OT  - *Breast cancer
OT  - *circulating tumor cells
OT  - *tissue plasminogen activator
EDAT- 2017/04/05 06:00
MHDA- 2017/04/14 06:00
CRDT- 2017/04/05 06:00
PHST- 2017/02/18 [received]
PHST- 2017/03/10 [revised]
PHST- 2017/03/13 [accepted]
AID - 37/4/1787 [pii]
AID - 10.21873/anticanres.11512 [doi]
PST - ppublish
SO  - Anticancer Res. 2017 Apr;37(4):1787-1791.

<?xml version="1.0" encoding="UTF-8"?>
<b:Sources SelectedStyle="" xmlns:b="http://schemas.openxmlformats.org/officeDocument/2006/bibliography"  xmlns="http://schemas.openxmlformats.org/officeDocument/2006/bibliography" >
</b:Sources>